Funding for this research was provided by:
Telethon Perth Children's Hospital Research Fund
Text and Data Mining valid from 2018-08-10
Received: 27 June 2017
Accepted: 6 July 2018
First Online: 10 August 2018
Ethics approval and consent to participate
: This study has received ethics approval from the Princess Margaret Hospital Human Research Ethics Committee (2015203EP), and reciprocal approval from The University of Western Australia Human Research Ethics Committee (RA/4/1/8024). Participants will be recruited from Princess Margaret Hospital in Perth, as well as General Practice, and Headspace Clinics (early intervention services for youth mental health disorders) in the Perth metropolitan area. This trial is also registered with the Therapeutic Goods Administration, with a Clinical Trial Notification number of CT-2016-CTN-01070-1.Prior to study participation, informed consent will be obtained from subjects and their parents/guardians by the study doctors. When obtaining informed consent from the patients and their parents/guardians, focus will also be given to outline the need for blood sampling in this study, and the potential risks of lowered mood in the short term whilst under the influence of ATD (which is in line with the main hypothesis with regard to Phase A). Consent will be obtained at an initial screening session where participants will be assessed for eligibility to participate in the study.
: Not applicable.
: FDZ was the recipient of an unrestricted award donated by the American Psychiatric Association (APA), the American Psychiatric Institute for Research and Education (APIRE) and AstraZeneca (Young Minds in Psychiatry Award). He has also received research support from the German Federal Ministry for Economics and Technology, the European Union (EU), the German Society for Social Paediatrics and Adolescent Medicine, the Paul and Ursula Klein Foundation, the Dr. August Scheidel Foundation, the IZKF fund of the University Hospital of RWTH Aachen University, the Telethon Kids Institute, the Telethon Perth Children’s Hospital Research Fund, the Princess Margaret Hospital Foundation, and a travel stipend donated by the GlaxoSmithKline Foundation. He is the recipient of an unrestricted educational grant, travel support and speaker honoraria by Shire Pharmaceuticals, Germany. In addition, he has received support from the Raine Foundation for Medical Research (Raine Visiting Professorship), and editorial fees from Co-Action Publishing (Sweden). SEM has received consultancy payments from p1Vital and has participated in paid speaking engagements for Lilly UK. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.